Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Clinical trial NCT05027425 · TERMINATED

Trial details

NCT number: NCT05027425
Sponsor: University of Cincinnati
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Cirrhosis Portal Hypertension

Start date: 2021-12-07
Primary completion: 2024-11-07
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.